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Abstract
Background and Aims: Current histological scoring systems do not subclassify cirrhosis.
Computer-assisted digital image analysis (DIA) of Sirius Red-stained sections measures
fibrosis morphologically producing a fibrosis ratio (collagen proportionate area [CPA]).
CPA could have prognostic value within a disease stage, such as cirrhosis. The aim of the
present study was to evaluate CPA in patients with recurrent hepatitis C virus (HCV)
allograft cirrhosis and assess its relationship with hepatic venous pressure gradient
(HVPG).
Methods: In 121 consecutively-transplanted HCV patients with HVPG, measured con-
temporaneously with transjugular liver biopsies, 65 had Ishak stage 5 or 6 disease (43 with
HVPG measurement). Biopsies were stained with Sirius Red for DIA, and the collagen
content was expressed as a CPA. In three cases, a tissue for Sirius Red staining was not
obtained, and the patients were excluded.
Results: Sixty-two patients were analyzed. The median HVPG was 8 mmHg (interquartile
range [IQR]: 5–10). Portal hypertension (HVPG  6 < 10 mmHg) was present in 30
(69.8%), and HVPG  10 mmHg in 13 (30.2%). The median CPA was 16% (IQR 10.75–
23.25). Median Child–Pugh score and HVPG were not significantly different between
Ishak fibrosis stage 5 or 6, whereas CPA was statistically different: 13% in stage 5 (IQR
8.3–12.4) versus 23% in stage 6 (IQR 17–33.7, P < 0.001). In the multivariate analysis,
CPA was the only variable significantly associated with clinically-significant portal
hypertension (HVPG  10 mmHg, odds ratio: 1.085, confidence interval: 1.004–1.172,
P = 0.040). A CPA of 14% was the best cut-off value for clinically-significant portal
hypertension (CSPH) and liver decompensation, which occurred in 24 patients. Event-free
survival was significantly shorter in patients with CSPH or with a CPA value  14%, or
with a combination of both.
Conclusion: In Ishak stages 5 and 6, CPA correlated with HVPG, but had a wider range
of values, suggesting a greater sensitivity for distinguishing “early” from “late” severe
fibrosis/cirrhosis. CPA was a unique, independent predictor of HVPG  10 mmHg. CPA
can be used to subclassify cirrhosis and for prognostic stratification.
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Introduction
Cirrhosis is defined histologically by the diffuse replacement of
the normal lobular architecture of the liver by regenerative paren-
chymal nodules surrounded by fibrous tissue. Liver biopsy
remains the gold standard for staging parenchymal liver disease
based on the degree of fibrosis and architectural distortion.
However, although all histological classification systems have cir-
rhosis as the most advanced stage, there are no accepted histologi-
cal criteria to determine the severity of cirrhosis. Conversely,
clinical classifications do score the severity of cirrhosis, such as
Child–Pugh or model for end-stage liver disease (MELD) scores,
or evaluate the occurrence of complications of cirrhosis, such as
ascites, varices, or bleeding.1 The concept of “severity of cirrhosis”
has significant clinical implications. Hepatic venous pressure gra-
dient (HVPG) has been confirmed as a good prognostic index by
several groups in relation to survival and complications.2 Compli-
cations of cirrhosis are known to develop once HVPG reaches a
threshold level of 10–12 mmHg, reflecting more severe portal
hypertension.3–6 This threshold is of prognostic value, and
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is termed “clinically-significant portal hypertension” (CSPH); it is
predictive of the development of cirrhosis complications6 and
allograft cirrhosis after liver transplantation for hepatitis C virus
(HCV) chronic liver disease.7
Theoretically, specific histological findings might also be able to
determine the severity of cirrhosis and predict the likelihood of
developing complications. This relationship would be of practical
clinical value, not only prognostically, but also in regard to assess-
ing the progression of cirrhosis, in assessing the potential revers-
ibility of fibrosis, and identifying patients for antifibrotic and other
therapies. Only two studies have evaluated this. Nagula et al.8
performed a study assessing the relationship between HVPG and
specific histological features using 43 liver biopsies with a diag-
nosis of cirrhosis, and evaluated whether any histological features
correlated with CSPH. They found that septal thickness and small
nodules were the only two independent associations with CSPH.
Another similar study9 of 47 patients with biopsy-proven cirrhosis
and HVPG measurements concluded that small nodularity and
thick septa are independent predictors of the presence of CSPH.
This was also the case in a study of 123 patients with predomi-
nantly alcoholic cirrhosis.10 These three studies suggest that cir-
rhosis can be subclassified histologically, and used similar
methods for evaluating nodule size and septum thickness, but is
not clear how the particular nodules or septa that were measured
were chosen in any histological section or microscopic field of
view. Large and small nodules can be present in different parts of
a single liver biopsy section; septal thickness is similarly variable
and is generally inversely related to nodule size. Indeed, thick
septa/small nodules and thin septa/large nodules reflect the pro-
portion of connective tissue (much of which is collagen in
advanced-stage liver disease) in the cirrhotic biopsies (i.e. collagen
proportionate area).
What is needed is a histological measurement that measures the
amount of fibrosis properly in advanced-stage liver disease. The
traditional histological scoring systems are categorical assign-
ments, and are neither quantitative in nature nor are they measure-
ments. Thus, the numbers assigned to the categories should not be
evaluated as continuous variables, nor be treated as numbers, as
there is no arithmetical relationship between them: stage 4 does not
mean twice the amount of fibrosis as stage 2.11 A proper fibrosis
measurement can be correlated with other continuous variables,
such as HVPG and non-invasive indices of fibrosis, including
transient elastography. Ideally, this histological fibrosis measure-
ment should be applicable to all stages of liver disease and to
monitor fibrosis progression/regression. One technique that fulfils
these requirements is the quantitative measurement of liver fibrosis
by a computer-assisted digital image analysis (DIA) of histological
sections that are stained histochemically by the PicroSirius Red
technique,11–13 which primarily identifies tissue collagen.14 The
quantity of bound stain correlates well with biochemically-
determined collagen content and morphometrically-determined
hepatic fibrosis.15,16 DIA uses segmentation of digital images to
measure the area of collagen and the area of tissue. This produces a
“fibrosis ratio” or collagen proportionate area (CPA). Other neces-
sary evaluations required for routine histological diagnoses can still
be made, and collagenous structures irrelevant to the disease
process (and which contribute to the variability between samples)
can be excluded precisely.11 We recently showed16 that CPA in a
cohort of patients with recurrent HCV after liver transplantation had
a good correlation with HVPG. For the purpose of comparison with
previous papers, we also showed a progression of CPA values with
increasing Ishak stages. In patients transplanted for HCV cirrhosis,
rapid progression to allograft cirrhosis develops in up to 30% after
5 years from liver transplantation,17 and the policy of scheduled
biopsies18–20 by several groups, including our own, to assess pro-
gression of recurrent HCV, provides an appropriate, if not optimal,
clinical setting to evaluate the relationship between CPA and
cirrhosis.
The aim of the present study was to assess the relationship
between CPA with HVPG and the clinical outcomes of allograft
liver biopsies in patients with Ishak stage 5 or 6 due to recurrent
HCV infection, and to assess changes in CPA in these patients who
had undergone more than one biopsy.
Methods
Between March 1990 and October 2008, we prospectively evalu-
ated a consecutive series of 121 patients with recurrent hepatitis C
after liver transplantation, who had serial transjugular liver biop-
sies (TJB); from 1999, TJB was combined with HVPG measure-
ments. All patients had been transplanted for HCV cirrhosis, had
received a cadaveric graft, and had been evaluated for at least
6 months’ post-transplant.17 We identified all patients with a his-
tological diagnosis of Ishak 5 or 6, and used the first biopsy in
which either stage was found as the “baseline” biopsy. All patients
were followed up with 3–6-monthly outpatient visits, and epi-
sodes of decompensation (ascites, variceal bleeding, encephalopa-
thy) were recorded. The study protocol conformed to the ethical
guidelines of the Declaration of Helsinki. All patients gave
written, informed consent for both the procedure and histological
evaluation.
TJB. All TJB procedures were performed in the X-ray suite by
experienced personnel (DP, JO’B, DY), as detailed elsewhere,21
using a 19G Tru-cut-type biopsy needle (Quick core; William
Cook Europe, Bjaeverkov, Denmark). We performed three, or
more recently, four passes22 through the same hepatic vein wall
(right or middle) to optimize the samples of liver tissue
obtained.21,22 We have previously shown that TJB compare well or
are superior to percutaneous biopsies23 for both the number of
portal tracts and total length.24
Biopsy specimen study. Liver biopsy samples were for-
malin fixed, paraffin embedded, and stained with hematoxylin–
eosin, Gordon and Sweet staining for reticulin, and chromotrope
aniline blue. Another section of tissue was stained with Sirius Red
for collagen quantification and determination of CPA by DIA.
Each biopsy sample was evaluated histologically, according to
Ishak et al.,25 for disease stage and grade of necroinflammatory
activity. For each biopsy, we recorded total length (length of each
fragment summed). Portal tracts were not counted, because rec-
ognition and enumeration of individual portal tracts in advanced
stage liver disease is not possible. The sections of each biopsy
stained with Sirius Red were used for DIA, which was performed
by one author (VC). The equipment setup used consisted of a
digital camera (Canon Powershot A640; Canon, Middlesex, UK;
attached to a close-up copystand with backlighting) connected to a
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compatible personal computer. The calibration of the camera setup
was 154 ¥ 154 pixels = 23 716 = 1 mm2. After whole-section
digital image capture, CPA was measured with Zeiss KS300 image
analysis software (Zeiss, Hertfordshire, UK). The CPA measure-
ment process included a manual editing step to eliminate image
artifacts, and operator-dependent thresholding to determine the
stained area of the section.
In our previous study,16 which evaluated our entire cohort of
patients with HCV recurrence after liver transplantation, we had
assessed intraobserver and interobserver variability by repeating
the CPA assessment using two sets of 20 biopsies (10% of cohort).
The concordance coefficients between the intraobserver and inter-
observer evaluations were 0.98 and 0.97, respectively.16
Hemodynamic study. Hepatic vein pressures were mea-
sured using a 5-F balloon catheter (Royal Flush plus Straight
Visceral Angiographic Beacon tip catheter; William Cook Europe,
Denmark), using the technique recently described.26 Three sets
of measurements were taken using monitor DATASCOPE
MEDICAL 2000A 6189-L7 (London, UK), setting the external
zero point at the mid-axillary line. A difference  1 mmHg of the
free hepatic pressure gradient with the measured inferior vena cava
pressure was considered acceptable. Wedged hepatic vein pressure
was measured for at least 1 min each time. The trace was examined
to ensure “occlusion”. If there was patient movement or breathing
artifacts, measurements were repeated. HVPG (the difference
between the wedged and free hepatic pressure gradient) was cal-
culated as the mean of the three measurements.
Statistical analysis. All data were analyzed using the statis-
tical package SPSS (version 15.0; SPSS, Chicago, IL, USA). Con-
tinuous variables were summarized as median and interquartile
range (IQR), and categorical variables as frequency and percentage.
Correlation between variables was evaluated by Spearman correla-
tion. Significance testing was two sided and set to  0.05.
Comparisons between unpaired samples for HVPG and CPA
were made using the Mann–Whitney test, whereas paired com-
parisons in the same patient for HVPG and CPA were made using
the Wilcoxon test. Intraobserver and interobserver variability was
assessed by calculation of the concordance coefficient.
Logistic regression analysis was used to determine independent
associations with the HVPG cut-offs of  6 mmHg and
 10 mmHg, representing the presence of portal hypertension26
and clinically significant portal hypertension, respectively.5 Dec-
ompensation was defined as ascites, variceal bleeding, or hepatic
encephalopathy. We evaluated the proportion of patients who suf-
fered decompensation and the time to the event by Kaplan–Meier
plots and log–rank analysis.
Results
Ishak stage score 5 or 6 was diagnosed in 65 patients at a median
of 48 (range: 12–135) months after liver transplantation. In three
cases, a tissue for Sirius Red staining was not obtained, and the
patients were excluded. Among the 62 patients, 27 (56.5%) had a
diagnosis of developing cirrhosis (Ishak 5), and 35 (43.5%) of
complete cirrhosis (Ishak 6). A total of 24 patients developed
decompensation (18 ascites, 2 ascites and hepatorenal syndrome, 3
variceal bleeding, 1 portosystemic encephalopathy [PSE]) at a
median of 22 months (range: 4–56). HVPG at the time of histo-
logical diagnosis of developing or complete cirrhosis was mea-
sured in 43 patients (25 HVPG measurement in Ishak 5, and 18 in
Ishak 6), with a median value of 8 mmHg (IQR: 5–10). Portal
hypertension (HVPG 6 mHg) was found in 30 patients (69.8%),
and CSPH (HVPG  10 mmHg) in 13 patients (30.2%).
The median CPA value was 16% (IQR: 10.75–23.25) for all 62
patients. Analyzing only the 43 patients with HVPG measure-
ments, the median CPA value was 16.4% (IQR: 12–22). The dif-
ference between the medians of Child–Pugh score (CPS) and
HVPG for stages 5 and 6 were not statistically significant (CPS: 5
[IQR: 5–6] vs 6 [IQR: 5–8], P = 0.132; HVPG: 7 mmHg [IQR:
4–9.5] vs 8.5 mmHg [IQR: 5.75–12.25] P = 0.097), as we have
noted before.21 However, the CPA was statistically significantly
different: in stage 5, the median CPA was 13% (IQR: 8.3–12.4),
and in stage 6, it was 23% (IQR: 17–33.7) (P < 0.001; Table 1).
Overall, there was a significant correlation between CPA and
HVPG (r = 0.370, P = 0.017; Fig. 1).
We subdivided patients with HVPG values lower or higher than
10 mmHg (CSPH) as previously published.3
Table 1 Median and IQR values of CPS, HVPG and CPA, according
to Ishak stage score in all 62 patients, and in the 43 with HVPG
measurement
Variable Ishak 5 (35 points) Ishak 6 (27 points) P-value
Median value (IQR)
CPS 5.0 (5.0–6.0) 6.0 (5.0–8.0) 0.132
CPS† 5.0 (5.0–6.5) 6.0 (5.0–8.0) 0.243
HVPG mmHg† 7.0 (4.0–9.50) 8.5 (5.75–12.25) 0.097
Mean CPA (%) 13.0 (8.3–16.4) 23.0 (17.0–33.7) < 0.001
CPA (%)† 13.8 (8.0–19.0) 18.8 (16.8–26.1) 0.009
†Forty-three patients with HVPG measurement.
CPA, collagen proportionate area; CPS, Child–Pugh score; HVPG,
hepatic venous pressure gradient; IQR, interquartile range.
Figure 1 Correlation between collagen proportionate area (CPA) and
hepatic venous pressure gradient (HVPG) in 43 patients with recurrent
hepatitis C virus-related Ishak stage 5 or 6 after liver transplantation.
V Calvaruso et al. Collagen proportionate area and liver decompensation
1229Journal of Gastroenterology and Hepatology 27 (2012) 1227–1232
© 2012 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd
We evaluated whether three parameters, the CPS, the Ishak
stage (5 or 6) or grade, and CPA, were associated with portal
hypertension (HVPG 6 mmHg) or CSPH (HVPG 10 mmHg)
in a multiple regression model. CPA was the only variable inde-
pendently associated with clinically-significant portal hyperten-
sion (odds ratio: 1.085; confidence interval: 1.004–1.172,
P = 0.040; Table 2).
Fourteen of the 43 patients (32.6%) with HVPG measurements
suffered decompensation: 11 ascites, two variceal bleeding, and
one PSE. This occurred at a median of 18.5 months (range: 4–48)
after the histological diagnosis of advanced fibrosis or cirrhosis. In
the 19 patients without HVPG measurements, who were followed
for a median of 48 months (5–132), 10 (52.6%) decompensated (7
ascites, 2 ascites and hepatorenal syndrome, and 1 variceal bleed-
ing) at a median time of 25 months (range: 5–56).
By Kaplan–Meier methods, the event-free survival (i.e. to first
episode of decompensation) was significantly shorter in patients
with CSPH (log–rank test, P = 0.039; Fig. 2).
For liver decompensation, the best area under receiver operat-
ing curve for CPA was 0.65 (95% CI: 0.55–0.86), and the best
cut-off value was 14% CPA, with 71% sensitivity and 57%
specificity.
The event-free survival was significantly shorter in patients with
CPA values equal or higher than 14% (log–rank test, P = 0.042;
Fig. 3).
Upon dividing the patients into four different groups according
to CPA cut-off values, and CSPH, a marginal difference was
found between the event-free survival in patients with a CPA
value equal or higher than 14% and CSPH (log–rank test,
P = 0.051; Fig. 4).
Seventeen patients of the 43 with Ishak 5 or 6 had further TJB
combined with HVPG measurement. The differences between the
medians of CPS, HVPG, and CPA values are shown in Table 3.
Only the CPA value was found to be different between the first and
subsequent biopsies (15.2% [IQR: 8.3–20.8] vs 17% [IQR: 10.6–
21.4], P = 0.079). All but one patient had an increased CPA value
in the second biopsy. This patient had a diagnosis of complete
cirrhosis (Ishak stage 6) in the first biopsy, and Ishak stage 5 in the
second biopsy, without any change in HVPG value (7 mmHg in
both procedures).
Discussion
Measuring the severity of cirrhosis other than by clinical scores
that incorporate complications (e.g. ascites and encephalopathy
Table 2 Clinical and histological associations with HVPG 6 mmHg and HVPG 10 mmHg (CSPH) in 43 patients with recurrent HCV infection, and
Ishak stage 5 or 6 after liver transplantation
Univariate analysis Multivariate analysis
HVPG
< 6 mmHg  6 mmHg P-value OR (95% CI) P-value
Ishak grading score 5 (3–6) 6 (4–7) 0.188
Ishak staging score = 6 4/14 (28.6%) 13/28 (46.4%) 0.323
CPA (%) 12.0 (7.5–17.2) 17.4 (13.0–24.0) 0.096 1.057 (0.978–1.142) 0.165
CPS 6.0 (5–7) 5 (5–8) 0.354
HVPG OR (95% CI) P-value
< 10 mmHg  10 mmHg P-value
Ishak grading score 6 (4–6) 6 (4.5–7) 0.723
Ishak staging score = 6 11/29 (37.9%) 5/13 (38.5%) 0.823
CPA (%) 15.7 (8.2–19.0) 19.2 (16.0–28.7) 0.054 1.085 (1.004–1.172) 0.040
CPS 5 (5–7) 6.0 (5–10) 0.550
CI, confidence interval; CPA, collagen proportionate area; CPS, Child–Pugh score; HCV, hepatitis C virus; HVPG, hepatic venous pressure gradient;
OR, odds ratio.
Figure 2 Event-free survival (first episode of decompensation: ascites,
variceal bleeding, or encephalopathy) according to clinically-significant
portal hypertension (hepatic venous pressure gradient [HVPG]
 10 mmHg) in 43 patients with recurrent hepatitis C virus infection and
Ishak stage 5 or 6 after liver transplantation. Log–rank = 0.039. ( )
HVPG < 10 mmHg, ( ) HVPG  10 mmHg.
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[Child–Pugh) or renal function [MELD]) would be a useful clini-
cal tool. At present, only HVPG provides prognostic information
before decompensation.6,7 However, the spread of HVPG values is
low in early cirrhosis. We previously found that CPA had a greater
discrimination for the severity of fibrosis at lower HVPG values.16
In our current study, which specifically evaluated 62 patients with
cirrhosis, CPA had a median value of 16% (IQR: 10.75–23.25)
with Ishak stage 5 or 6 disease, with increasing values from stage
5 to 6. We again found a significant correlation with HVPG.
Interestingly, while differences in HVPG were not statistically
significant between stages 5 and 6, differences in CPA were sig-
nificantly different, suggesting a greater sensitivity to distinguish
changes in advanced stage liver disease, in the same way that CPA
gave a greater spread of values for low HVPG values.16 By logistic
regression analysis, we also found that CPA had a unique and
independent association with CSPH, indicating a high risk of
decompensation. A CPA of 14% or more was associated with a
higher rate of liver decompensation, as is the case with CSPH.7
The analysis of the 17 patients with cirrhosis, who had repeated
biopsies combined with HVPG measurements, showed that only
CPA could be shown to increase over time, which was not the case
with HVPG over the study intervals. Thus, CPA in cirrhosis, as
well as in precirrhosis,16 has potentially greater sensitivity for
measuring the progression and regression of fibrosis. CPA could
provide a basis for a more refined histological subclassification of
cirrhosis. Although our results show the value of CPA to further
classify cirrhosis histologically, the technique must be studied in
other forms of chronic liver disease, before it can be considered a
“universally”-applicable tool. It also needs to be validated in other
centers. A limitation of the technique is that extra time is added to
the histological examination, and the need for the new equipment
(16), but the current cost of this is under 10 000 pounds sterling.
Similar concepts concerning histological severity, but assessing
the size of nodules and thickness of septa in cohorts of 438 479 and
123 patients,10 have also suggested that histological features in
cirrhosis have prognostic value. However, in these studies, it is not
clear which nodule or septum constitutes the reference structure in
any particular microscopic field.
CPA is a sensitive index for the histological assessment of
fibrosis, and being a measurement expressed as a continuous vari-
able, it is well suited to assess therapies that might affect fibrosis,
including both antifibrotics and antiviral drugs, particularly in
patients within the category of cirrhosis in whom current histo-
logical scoring systems cannot assess degrees of severity of cir-
rhosis. As previously documented,27 with regard to the correlation
of transient elastography and high HVPG, we also found that at
higher values of HVPG, the correlation between CPA and HVPG
was not as good. Although the dynamic component of HVPG
might explain why the correlation of HVPG with CPA, or indeed
Figure 3 Kaplan–Meier plot of event-free survival (first episode of
decompensation) according to collagen proportionate area (CPA) value
in 62 patients with recurrent hepatitis C virus infection and Ishak stage
5 or 6 after liver transplantation. Log–rank = 0.042. ( ) CPA < 14%,
( ) CPA  14%.
Figure 4 Event-free survival (first episode of decompensation) accord-
ing to collagen proportionate area (CPA) value and clinically-significant
portal hypertension (hepatic venous pressure gradient [HVPG]
 10 mmHg) in 43 patients with recurrent hepatitis C virus infection
and Ishak stage 5 or 6 after liver transplantation or greater/equal to
10 mmHg. Log–rank = 0.051. ( ) HVPG < 10 mmHg, CPA < 14%,
( ) HVPG < 10 mmHg, CPA  14%, ( ) HVPG  10 mmHg,
CPA < 14%, ( ) HVPG  10 mmHg, CPA  14%.
Table 3 CPS, HVPG, and CPA in first and last paired biopsies in 20
patients who had baseline Ishak stage 5 or 6 in their first biopsy
Variable (median
value IQR)
1st biopsy 2nd biopsy P-value
CPS 5.0 (5.0–5.8) 5.0 (5.0–6.3) 0.852
CPA (%) 15.2 (8.3–20.8) 17.0 (10.6–31.4) 0.079
HVPG mmHg† 8.0 (6.8–11.0) 8.0 (5.5–12.0) 0.903
†Seventeen patients with HVPG measured with during both liver
biopsies.
CPA, collagen proportionate area; CPS, Child–Pugh score; HVPG,
hepatic venous pressure gradient; IQR, interquartile range.
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transient elastography, is not as good at higher HVPG values,27
another study28 did not find as good a correlation between transient
elastography and HVPG, so this issue needs further evaluation.
Studies evaluating the pharmacological reduction of HVPG should
be able to assess how much of the HVPG might be due to fibrosis
and how much due to dynamic intrahepatic vascular changes by
assessing CPA.
In the present study, we have shown that CPA as a continuous
variable is a suitable histological measurement to assess the degree
of fibrosis in advanced-stage liver disease, including established
cirrhosis, and would be a better marker compared to histological
staging systems for comparisons with direct and indirect non-
invasive measures, currently advocated for the evaluation and
quantitation of hepatic fibrosis.29
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